Genetic analysis in our laboratory of families with generalized thyroid hormone resistance (GTHR) has demonstrated tight linkage with a locus, c-erbAft, encoding a nuclear T3 receptor.
Introduction
The c-erbA genes encode thyroid hormone-activated transcriptional regulatory proteins, the triiodothyronine (T3) receptors (1, 2) . These proteins belong to a superfamily of nuclear receptors including those for steroid hormones, vitamin D, and retinoic acid, whose action is to modulate the transcriptional activity of certain genes in response to hormonal signals. Thus far, two different subfamilies of T3 receptors, a and /3, have been characterized (3) (4) (5) (6) . The c-erbAa gene has been located on chromosome 17q 11.2-21 (7) and the same gene encodes for two alternatively spliced forms of proteins, a 1 and a2 (4) . The c-erbA/3 gene, encoding the two forms ofthe /3 receptor, /3 and /32, has been mapped to chromosome 3p2 1-25 (8) . The /32 subtype, a pituitary-specific T3 receptor, has been found in rats (9) but not yet in humans. The a,, /I3, and 2 forms all bind thyroid hormone, while the a2 does not; however, the latter may also play a physiological role in hormone action since it inhibits the transcriptional effects of the a, and /3 receptors (10) . The diversity of T3 receptors suggests that specific cell responses to thyroid hormone may be the result ofdifferent levels ofexpression of each one of these genes. However, the relative importance of each of these receptor subtypes in mediating thyroid hormone action in different tissues is not established (1 1) .
The syndrome of generalized thyroid hormone resistance (GTHR)' is characterized by elevated serum levels of free thyroid hormones with inappropriately elevated thyroid-stimulating hormone (TSH) as well as clinical and biochemical evidence of decreased thyroid hormone action (12, 13) . These patients also show unresponsiveness to large doses of exogenous thyroid hormones. Recent studies have demonstrated a genetic linkage between the c-erbA/ gene and thyroid hormone resistance in several families (14, 15) . Subsequently, in three unrelated families three different point mutations were found in different areas of the ligand binding domain resulting in nonconservative amino acid substitutions (15) (16) (17) . In addition, two families have been reported with large and small deletions, respectively, in the c-erbA/3 gene (18, 19) . Two of these mutations as well as the small deletion resulted in decreased T3 affinity for the receptor (16, 19, 20) .
In the present studies we have attempted to elucidate the molecular basis ofGTHR in several additional kindreds evaluated at the National Institutes of Health. Direct sequencing of polymerase chain reaction (PCR)-amplified genomic DNA has permitted rapid and accurate detection of novel point mutations in exons 9 and 10 of c-erbA/3 gene in seven of nine additional GTHR kindreds studied. In both familial (autosomal dominant) and sporadic cases, as well as one with unknown inheritance, affected members were all heterozygous. The finding ofcommon biochemical features ofthyroid hormone resistance consistently associated with mutation in the ligand binding domain of the T3 receptor contrasts with the absence of a distinct clinical phenotype in this genetic condition. Nonetheless, the mutations found are clearly grouped in two clusters: one in the center ofthe ligand-binding domain involving the 5' end of the dimerization subdomain and the 3' end of the taui transcriptional subdomain (21) , and the other in the distal 3' region of the ligand-binding domain which is thought to be involved in direct contact with T3 (22, 23 (2) , rather than to the revision suggested by Sakurai et al. (25) , who assumed a different translational initiation site. Exons 9 and 10 correspond to exons G and H in the genomic structure described by Sakurai et al. (25) . Allele-specific amplification. In those cases in which a mutation did not result in gain or loss of a restriction site, allele-specific polymerase chain reaction (ASPCR) amplification ofthe exon was used to confirm and/or detect other affected members ofa kindred. The principle ofthe method is that a PCR amplification would not proceed if the 3' end of one of the primers did not match the complementary base of the template (30) . Oligonucleotides of 14 bases were prepared in which the 3' (sense) or 5' end (antisense) base matched either the normal or the mutant. Products of amplification are detected only in samples from affected persons when the "mutant" primer is used. In certain instances the efficiency of the reaction with the mutant primer was low and hybridization with a labeled probe (random primer-labeled, linearized plasmid containing the c-erbA(# insert) was used to visualize the amplification products.
Chemical mismatch. The method of Cotton et al. (31) as modified by Grompe et al. (32) of chemical mismatch cleavage has also been used in certain cases for the mapping of mutations in DNA heteroduplexes formed with amplified c-erbAfl exons 9 or 10 from control subjects and patients with GTHR.
Preparation of mutant receptors cDNA. cDNA clones of exon-10 c-erbA#l mutants (cases Q-W, O-K, and P-V) were prepared as follows:
exon-I 0 was amplified by PCR from genomic DNA as described above and the fragment cloned into pGEM4Z vector. The DNA fragment from BglII to HindIll was subcloned into the wild type human placental c-erbAI# clone, peal l (2). cDNA for the exon 9 mutation E-D was prepared from the template pealO by the splicing overlap method of PCR (33) using complementary internal oligonucleotide primers containing the E-D mutation and 3' and 5' primers overlapping Styl and BglII sites of the wild type sequence. After StyI and BglII restriction digest, the fragment was substituted for the corresponding region of peall.
In vitro translation. In vitro translation ofthe receptors was carried out with a reticulocyte lysate L-[35S]-methionine translation kit from
Dupont-NEN, Wilmington, DE, following the protocol described by Usala et al. (20) . Products ofthe translation were analyzed by 10% SDS PAGE.
T3-binding assay. A portion ofthe in vitro translation product was used for studying T3-receptor binding by the nitrocellulose filter assay 
Results
Thyroid function tests. Table I summarizes the thyroid function tests of representative individuals from each kindred whose genomic DNA was used for amplification and sequencing of the c-erbAfl gene. In all cases, the TSH was inappropriately high and would be expected to be < 0.1 sU/ml in the face of elevated levels of both total and free thyroid hormones. Attention deficit-hyperactivity disorder was the most common clinical feature in these patients and growth retardation was present in two families (13, 15) . Perhaps the most striking finding was the absence of any other consistent phenotypic characteristics associated with this clinical syndrome. obviates the need to sequence multiple samples, as with conventional cloning techniques. Fig. 1 A illustrates an example showing a fragment of the sequencing ladder of amplified c-erbAfl exon 9 from patient N-Ni. A G --A transition mutation is shown as distinct G and A bands at the same position in the sequencing ladder. The intensity ofthe bands is less than ifonly a single allele were expressed. As expected, sequencing of the antisense strand ( Fig. 1 A) shows T and C bands. In all cases both DNA strands were asymmetrically amplified and the products used to sequence in the sense and antisense directions. Sequencing of both strands has been essential in resolving all the possible ambiguities intrinsic to the sequencing method.
A C Fig. 1 B shows the wild-type and case E-D4 sequencing ladders of a fragment of exon 9 in which two mutations were found within a narrow range of bases. The G to A transition at nucleotide position 1234 is nonconservative, whereas the G to C transversion at nucleotide 1242 does not change the coded amino acid and is therefore neutral. Another advantage of the simultaneous sequencing of two or more alleles is that, in heterozygous individuals, the overlapping of the sequencing ladders facilitates the detection ofbase insertions and/or deletions that otherwise might have been missed if a cloned allele was sequenced. Pro4-Thr443-Glu44-Leu44_
Leu449_Phe 450 Lxu451-GU452_VaI453_Phe4U_GIU455
Asp4l to the following which is two amino acids longer: Pro442-His443-Aro444-Thr44_Leu446_pro447
Pro443-Phe449-Val4s50LeU451-Gly452_Ser453Va 454_
Arg 455 -GIy456_LeU457-ASp458.
Clustering (codons 443 --458) that changes the carboxy-terminal amino acids from 443 to 456 and increases the polypeptide chain length by two amino acids. The ladders in Fig. 1 C are sense and antisense from case P-V1. The antisense ladder has unusual appearance with duplicated bands at multiple positions. In contrast, the sense ladder shows a normal appearance except for the first few bands at the top ofthe sequence. The sequences shown in Fig. 1 C could only be compatible with a base insertion and/or deletion in only one allele and in a position close to the 3' end of the template. Fig. 1 (15) (16) (17) . The mutation in kindred Q-W, in nucleotide 1642, affects codon 448 in which a mutation has been reported (14) ; however, the substituted nucleotide is not the same and therefore the encoded amino acid is also different, Pro"8 -0 Thr"8 instead of Pro"8 -* Gln"8. Similarly, the mutation in G-S affects the same codon (340) as did the other previously reported mutation (16) Table II and Discussion). the presence of the new restriction site was consistently detected in all the kindred members clinically affected. A case showing the opposite conditions, sporadic inheritance and loss of a unique restriction site, is shown in Fig. 3 B. The pattern of fragments as in the case in Fig. 3 A, is the result of overlapping the ladders obtained by the enzymatic digestion of both the wild-type and the mutant alleles. These observations thus provide further evidence of the heterozygosity of these cases. ASPCR amplification (30) and/or chemical cleavage of mismatched heteroduplexes (31) were used successfully in those cases in which a mutation did not result in gain or losses ofrestriction sites. The chemical cleavage method proved to be more cumbersome and less reliable than ASPCR, and its use is probably more appropriate for screening purposes and gross topographical location of mutations. Fig. 3 C shows the pedigree of kindred Q-W and the result of the hydroxylamine action on the heteroduplexes formed with amplified exon-10 DNA from wild type and from each one ofthe kindred components. The heteroduplex cleaved only in the affected members (Fig. 3 C) , indicating once again a definite correlation between the clinical syndrome of thyroid hormone resistance and the presence of a mutation in the ligand-binding domain of the c-erbAI3 gene. However, we found ASPCR to be the method of choice due to its speed and technical simplicity. Fig. 3 D exem- plifies the results obtained with this method in a kindred with familial inheritance ofa mutation in exon-IO of c-erbAf3. Only DNA from the clinically affected member was amplified when the 3' end base of the antisense primer matched the mutation previously detected by sequencing.
Functional properties offour selected mutations. In four of the seven mutations T3-binding studies were performed. These four mutations were chosen on the basis ofthe novelty oftheir topographical location (E-D and O-K), the unprecedented structural abnormality (case P-V, base insertion with frame shift in the 3' end of the gene) or the coincidence with a mutation in the same codon of a previously described case (Q-W). Table III shows the T3-binding affinities of wild-type and mutant receptors E-D, Q-W, O-K, and P-V. All mutant receptors showed impaired binding affinity compared to the wild-type. Case P-V, who has a base insertion at position 1627 with a resulting frame shift, was the most severely affected showing no detectable binding. Although case Q-W and a previously described case A-H (15) had mutations in the same codon but their mutations resulted in a different base change, their T3-binding affinities were markedly different. Case Q-W had a two-to fivefold greater binding affinity compared to A-H.
Discussion
Recent genetic analysis has demonstrated linkage of the syndrome of GTHR to the same locus as the c-erbA# gene on chromosome 3 in three families (14, 15) . The 
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Clustering of Thyroid Receptor Mutations in Generalized Thyroid Hormone Resistance 2127 m between the clinical syndrome and this gene strongly suggested that the molecular basis of this disease could be a mutation leading to quantitative and/or qualitative changes in the products of this gene. This hypothesis has been strongly supported by the elucidation of different nonconservative mutations in the ligand-binding domain (15) (16) (17) (18) (19) , as well as large and small deletions (18, 19) , of the c-erbA,3 gene in unrelated kindreds with generalized thyroid hormone resistance. Our current observations of seven novel point mutations in additional kindreds with thyroid hormone resistance greatly adds to the understanding of the function of the c-erbAf# receptor. The high percentage of GTHR patients in which a mutation has been found in two specific areas of the ligand-binding domain of the c-erbAf gene, seven kindreds described herein as well as in the three previously reported (15, 16, 17) families, is striking. Moreover, the absolute correlation of these mutations with the presence of disease in all of these kindreds supports the inference that they are the cause of the GTHR. Polymorphisms in these genes are rare (15, 16) and all of these nonconservative mutations produce major changes in the amino acids of the ligand binding domain (Table II) .
In two ofthe three previously reported mutants in the same two subdomain regions, hormone binding studies of in vitro translated mutant receptors clearly demonstrated decreased affinity for T3 (16, 20, 36) . The study of four of our cases, one from exon-9 (E-D) and three from exon-10, Q-W, O-K, and P-V, showed impairment of T3-binding to the in vitro translated receptors in all of them (Table III) . No apparent correlation was observed between topographical location ofthe mutation and degree of T3-binding impairment. Some ofthese mutant receptors have been shown to inhibit the ability of a cotransfected wild type receptor to mediate the T3 stimulation of a thyroid hormone responsive promoter (36, 37, 38) . These observations give further support to the hypothesis that the observed mutations in the c-erbAf3 gene are the cause of the GTHR syndrome. Moreover, it will ultimately be necessary to sequence the entire coding and adjacent noncoding regions of these mutant genes to exclude entirely the possibility of additional mutations which might affect receptor expression and/or function. This is unlikely in such an autosomal dominant disease, since it has been demonstrated that single amino acid changes in these regions of the ligand-binding domain, alone, are sufficient to account quantitatively for the T3 binding abnormalities observed in patients' fibroblasts (16, 20) . Thus the method of casette insertion of the respective mutations into wild-type cDNA excludes the possibility that any other unidentified mutations may have contributed to the decreased T3-binding observed in the present study.
Despite common biochemical features ofthyroid hormone resistance observed in all our patients (Table I) hormone-mediated transcriptional activation is more complex than previously thought and presumably involves the binding ofother proteins (38) (39) (40) (41) as well as the formation ofhomo-and heterooligomers with other nuclear receptors to form active protein-DNA-T3 complexes (42, 43) .
Structural organization ofc-erbA,1 gene. Fig. 2 shows schematically some ofthe structural-functional features ofthis gene as well as the locations of each mutation. The c-erbA13 gene belongs to a subtype of nuclear receptors (T3, vitamin D, and retinoic acid receptors) that share the sequence Glu-Gly-Gly in the DNA binding discriminatory region located at the base of the first Zn finger (23) . Recent evidence suggests the presence of at least three functional subdomains in the ligand binding domain of these receptors (23) . The ligand-binding subdomains, LI and L2 (Fig. 2) , are receptor specific and therefore are presumably involved in direct contact with ligand. These subdomains are required for high affinity binding of T3 (23) .
The dimerization domain (Fig. 2, DD) is a highly conserved region among this group of nuclear receptors (22) with nine repeats of seven amino acids (heptad repeats) with hydrophobic residues in positions 1, 5, and 8. These hydrophobic amino acids would provide in the coiled a-helix conformation of this polypeptide the points of interaction with other proteins, including receptors and other transcription regulatory factors (32, 40, 44) .
Deletion of the carboxy-terminal region produced ligandindependent, constitutively active receptors (45, 46) . This observation led to the hypothesis that the ligand-binding domain represses transactivation of transcription and the binding of ligand presumably relieves the repression. The subdomain tau, (Fig. 2) is a highly conserved region among the nuclear receptors (47, 48) that has also been implicated in the ligand-relieved expression (22, 45, 49) .
Functional implications ofthe topographical distribution of c-erbAf3 mutations. The mutations of the TR" gene. we. have described are not distributed evenly throughout exons 9 and 10, but rather in two well defined clusters located in the aminoterminal region ofthe dimerization subdomain and also in the L2 subdomain. Case E-D shows a singular location within the tau, subdomain. Although the associated clinical features vary, inappropriately elevated TSH levels and indicators of peripheral resistance to exogenous and endogenous hormone are common to all kindred and are evidence ofan impaired capacity ofall ofthe mutant receptors in vivo to inhibit expression of the TSH#3 gene and to regulate the expression ofother thyroid, hormone responsive genes. Additionally, each of the four mutations tested for T3-binding showed a decreased affinity for its ligand (Table III) . For mutations clustered in exon 10, this was not a surprise, particularly in view ofthe precise changes identified. The mutation in case O-K substitutes Met437 with valine.
Met437 is a highly conserved residue among nuclear receptors of this group and site-directed mutagenesis of this residue has been shown to result in a non-functional T3 receptor (50) . The case P-V, a C insertion with frame-shift, produces a change in most ofthe 14 carboxy-terminal amino acids. Deletions ofthis region have impaired or abolished T3 binding (22, 36) . The previously described mutant receptor (kindred A-H) in which histidine is substituted for Pro'8 displays a five-to tenfold reduction in the T3 binding affinity (20, 36) . Likewise, mutant Q-W, in which threonine replaces Pro"8, also demonstrates impaired T3 binding although to a lesser degree. The up to fivefold difference in the T3-binding affinity between A-H and Q-W probably indicates the relative importance of the amino acid substituted as well as its topographical location. Of note is the fivefold decrease in T3 binding affinity of mutant E-D (Table III), located in the tau, dimerization subdomain. This finding implies that this subdomain contains determinants of ligand-binding affinity as well as for ligand-relieved repression and is consistent with earlier data indicating that amino acids essential for normal T3-receptor interaction (19, 50, 51) lie outside ofthe subdomains, Ll and L2, required for ligand binding as defined by deletion mutagenesis of chicken c-erbA (21, 22) . Similarly, the currently described mutation of Gly' is also likely to decrease T3 binding as previously reported for another mutation of this codon (20) .
The absence of mutations among our cases in areas ofexon 9 and 10 outside the clusters may indicate that alterations of these regions of the protein produce phenotypes not recognizable as generalized thyroid hormone resistance. Alternatively, such alterations may result in no detectable functional abnormality. If the resistance phenotype were to reflect solely the decreased functionality of receptors acting in isolation, this would suggest that relatively few individual amino acids outside the clusters make a substantial contribution to this functionality. A more interesting possibility is suggested by the observation that the protein products of mutant alleles may inhibit the function of the normal product (or of other proteins) with which they interact in a "dominant negative" fashion (52) . This dominant negative effect has been shown in abnormal T3 receptors produced by site-directed mutagenesis (21, 51, 53) and may also underlie the inhibitory action ofretroviral or non-ligand binding forms ofthe T3 receptor (10, 21, 54, 55) . Structurally defective monomers, in which the capacity to dimerize is preserved, may form nonfunctional oligomers that inhibit the function of the normal receptor, perhaps through competition for binding to T3 response elements or for interaction with associated proteins. As described above, mutant receptors from patients with thyroid hormone resistance have also been shown to inhibit the transcriptional capacity of wild type receptors (36, 37) . In light ofthese observations, it is possible that alterations in areas of the protein other than the clusters, even iffunctionally detrimental, do not preserve the dominant negative effect. Such mutations, in allowing unimpaired functioning ofthe normal alpha and beta receptors from other alleles, may not cause a clinically significant abnormality ofthe thyroid axis. We note that none of the mutations results in an amino acid change expected to alter known protein-protein interactions; none of the three mutations within the dimerization subdomain disrupts a heptad repeat and no mutation to date has been identified in the region 281-300 which is precisely homologous to a region of rat c-erbA#,1 (aa 286-305) whose deletion disrupts interaction with certain accessory proteins (56, 57) . This does not exclude the possibility ofabnormal interactions as a result ofthese mutations and, indeed, some of the phenotypic diversity among kindreds may be related to specifically altered protein interactions in this domain as a result of subtle conformational changes perturbing dimerization and/or binding of other regulatory nuclear proteins.
In summary, the diversity of mutations described herein offers a unique tool for the study ofthe mechanisms ofthyroid hormone action. The ultimate correlation offunctional as well as physicochemical properties ofdifferent mutant T3 receptors with clinical and biochemical features in various kindreds should yield new insights into the complex interactions involved in regulation of gene transcription.
